An arsenic oxide in which arsenic and oxygen atoms are present in the ratio 2:3.
Chemical ID:
MESH:C006632
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Acetylcysteine inhibits the reaction [Arsenic Trioxide promotes the reaction [CASP9 protein binds to CYCS protein]]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; Arsenic Trioxide promotes the reaction [CYCS protein binds to CASP9 protein]
Acetylcysteine inhibits the reaction [Arsenic Trioxide results in decreased expression of CASP9 protein]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Arsenic Trioxide affects the reaction [lipopolysaccharide, E coli O55-B5 affects the cleavage of CASP9 protein]; Arsenic Trioxide promotes the reaction [Drugs, Chinese Herbal results in increased expression of CASP9 protein modified form]; Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP9 protein; Drugs, Chinese Herbal promotes the reaction [Arsenic Trioxide results in increased expression of CASP9 protein modified form]
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin promotes the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; 3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP9 protein]; [Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP9 protein; [Arsenic Trioxide co-treated with Plant Extracts] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Curcumin co-treated with Arsenic Trioxide] results in increased cleavage of CASP9 protein; [Dasatinib co-treated with Arsenic Trioxide] results in increased cleavage of CASP9 protein; [Sulindac co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Valproic Acid co-treated with Arsenic Trioxide] results in increased expression of CASP9 mRNA; [Valproic Acid co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; Acetylcysteine inhibits the reaction [Arsenic Trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]]; Acetylcysteine inhibits the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]]; AKT1 mutant form promotes the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; ARL6IP5 protein promotes the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; Arsenic Trioxide analog results in increased cleavage of and results in increased activity of CASP9 protein; Arsenic Trioxide promotes the reaction [Dasatinib results in increased cleavage of CASP9 protein]; Arsenic Trioxide promotes the reaction [Ethacrynic Acid results in increased cleavage of CASP9 protein]; Arsenic Trioxide promotes the reaction [lonidamine results in increased cleavage of and results in increased activity of CASP9 protein]; Arsenic Trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]; Arsenic Trioxide promotes the reaction [Sorafenib results in increased activity of CASP9 protein]; Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP9 protein; Arsenic Trioxide results in increased expression of and results in increased cleavage of CASP9 protein; BCL2 protein inhibits the reaction [Arsenic Trioxide promotes the reaction [lonidamine results in increased cleavage of and results in increased activity of CASP9 protein]]; BCL2 protein inhibits the reaction [lonidamine promotes the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP9 protein]]; BCL2L11 mutant form inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Dasatinib promotes the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; Deoxyglucose promotes the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP9 protein]; Fluorouracil promotes the reaction [Arsenic Trioxide results in decreased expression of CASP9 protein]; Genistein promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; GSTP1 mutant form promotes the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; HSF1 protein affects the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; KNK 437 promotes the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; lonidamine promotes the reaction [Arsenic Trioxide results in increased cleavage of and results in increased activity of CASP9 protein]; MAPK8 protein affects the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; MCL1 mutant form promotes the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP9 protein]; MIR203A protein promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Poly I-C promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; salvin promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP9 protein]; Sorafenib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; STMN1 inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP9 protein]; TNF protein promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]
